Drug intelligence / Profile preview

Diabecinn

Development stage: Unknown
Lead developer: OTC Pharma
Administration: Oral

Overview

Diabecinn is an oral botanical extract derived from cinnamon (likely *Cinnamomum* species bark) developed by OTC Pharma for the management of type 2 diabetes mellitus. It is a purified aqueous extract containing polyphenols and flavonoids that are believed to possess insulin-sensitizing and glucose-lowering properties. The extract is thought to modulate insulin signaling pathways and glucose metabolism, although its specific molecular targets remain poorly defined. Diabecinn has been evaluated in randomized, placebo-controlled clinical trials to assess its metabolic effects on blood glucose and insulin sensitivity in diabetic patients.

Brand names: Diabecinn
Other names: cinnamon extractaqueous cinnamon extract

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on Diabecinn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diabecinn.

Explore the full profile